

HOW TO MEASURE & IMPROVE QUALITY OF LIFE IN CUTANEOUS T-CELL LYMPHOMA

Prof. Julia Scarisbrick

Centre For Rare Diseases University Hospital Birmingham Centre for Rare Diseases University Hospitals Birmingham NHS Foundation Trust

Ms Jenni Burrows Patient Advocate





Content

- How's Health Related Quality of Life (HRQoL) impaired in CTCL?
- How do we measure HRQoL in CTCL?
- How we may improve HRQoL in CTCL?
- How should we currently best improve HRQoL?
- a) Better treatments
- b) Improved symptom control
- c) More psychological support
- d) Increased patient information





Why is quality of life Reduced in cutaneous T-cell lymphoma?


- CTCL is a visual disease
- Associated with disabling symptoms such as intractable itching (pruritus), pain, burning of skin
- CTCL is also a malignant disease of the skin with the worry of a cancer diagnosis
- Specific factors such as large or malodorous tumours, hearing loss, tiredness (malaise) and temperature dysregulation (hot/cold/shivering) may occur which are not typical of other skin diseases and may impede patients well being



Webinars **Cutaneous Lymphoma** EuroBleedNet[®] Topic on Focus



Measuring QoL/HRQoL



Network Hematological Diseases (ERN EuroBloodNet)

European

letwork

complex diseases

leference

HRQoL: Terminology

 Health related QoL (HRQoL) –focuses on the effects of illness and specifically treatment on QoL

European Organisation or Research & Treatment of Cancer (EORTC) definition of HRQoL - the subjective perceptions of both the positive & negative aspects of cancer patients' symptoms, including physical, emotional, social & cognitive functions &, importantly, disease symptoms & side effects of treatment

- Issues are symptoms such as itching/pain can be measured by selecting 'items' which are questions that encompass the issues
- Measures are the HRQol questionnaires developed to test a persons' health state by asking items on the relevant issues for their disease



Hematological

Diseases (ERN EuroBloodNet)

Webinars **Cutaneous Lymphoma** EuroBloodNet Topic on Focus Patterns' Oreanitration

CTCL HRQoL Issues



Painful hands



Pain

Disfiguring



Visual loss/hearing loss



for rare or low prevalence complex diseases

Network Hematological Diseases (ERN EuroBloodNet)



Fungating malodorous tumours



Weeping, painful visual lesions




Itching





CTCL issues affecting HRQoL

O Network





How we Measure Quality of Life in CTCL; Current situation

- We combine several QOL questionnaires to cover most aspects of cutaneous lymphoma (average of 3-4 per study)
- A variety of questionnaires are used & include;
 - The Functional Assessment of Cancer Therapy– General (FACT-G)
 - EORTC QLQ-C30 questionnaires
 - EQ-5D-3L (from Euro QOL gp)
 - Skindex 29
 - 12 item MF/SS CTCL questionnaire patientslikeme[®]
 - Illness Perception Questionnaire (IPQ-R)
 - Pruritus Visual Analog Scale, Pruritus scale, VASitch, Pruritus related Life Quality Index (PLQI), Likert scale & Itchy QoL
- This is time consuming for the patient and combining different questionnaires makes results to interpret and compare between studies as there is no standard combination






Skindex-29 Questionnaire Emotions **Symptoms** Functioning = Global 10 items 7 items 12 items All the time Likert Often Never Rarely Sometimes Scale 4 points 5 points 1 point 2 points 3 points 100 0 Linear Max. Effect Scale No effect Data Analysis Variables associated with worse QoL **Descriptive Statistics Multivariate regression** Independent factors associated with worse QoL





Alcanza Study - QoL per changes in symptom domain by Skindex-29 questionnaire

 Patient-reported QoL assessed by Skindex-29 questionnaire showed significantly greater symptom reduction for patients receiving brentuximab vedotin versus physician's choice (mean maximum reduction –28.08 vs –8.62; p<0.001)






Vertexpression
Vertexpression
Vertexpression
Diseases (ERN EuroBloodNet)




Mavoric Study: Patient-reported symptom reduction as measured by the Skindex-29 scale



CDF, cumulative distribution function


 The Skindex-29 Symptoms Scale scores demonstrated statistically significant improvements in favor of the mogamulizumabtreated patients vs the vorinostat-treated patients at Cycles 3, 5, and 7 (P<0.05)



 Median time to meaningful deterioration on the Skindex-29 Symptoms Scale was 27 months for mogamulizumab versus 7 months for vorinostat







BJD British Journal of Dermatology

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

K. Molloy (D,¹ C. Jonak,² F.J.S.H. Woei-A-Jin,³ E. Guenova,⁴ A.M. Busschots,³ A. Bervoets,³ E. Hauben,³ R. Knobler,² S. Porkert,² C. Fassnacht,⁴ R. Cowan,⁵ E. Papadavid,⁶ M. Beylot-Barry (D,⁷ E. Berti,⁸ S. Alberti Violetti,⁸ T. Estrach,⁹ R. Matin,¹⁰ O. Akilov (D,¹¹ L. Vakeva,¹² M. Prince,¹³ A. Bates,¹⁴ M. Bayne,¹⁵ R. Wachsmuch,¹⁶ U. Wehkamp,¹⁷ M. Marschalko,¹⁸ O. Servitje,¹⁹ D. Turner,²⁰ S. Weatherhead,²¹ M. Wobser,²² J.A. Sanches,²³ P. McKay,²⁴ D. Klemke,²⁵ C. Peng,¹ A. Howles,¹ J. Yoo,¹ F. Evison¹ and J. Scarisbrick¹

¹University Hospitals Birmingham, Birmingham, U.K.

Br J Dermatol. 2020 Mar;182(3):770-779







To identify factors associated with poorer health-related quality of life (HRQoL) in patients newly diagnosed with MF/SS

Methods:

• Patients enrolled into Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) had their HRQoL assessed using the Skindex-29 questionnaire & scores were analysed in relation to patient- and disease-specific characteristics.

Results:


The study population consisted of 237 patients [3:2 male:female; median age 60 years, 179 early MF and 58 d advanced MF/SS

- In univariate analysis HRQoL was worse,
 - 1. Female gender
 - 2. Alopecia
 - 3. Sezary syndrome
 - 4. Late-stage MF
 - 5. Elevated blood serum LDH
 - 6. High skin mSWAT count
 - 7. Confluent erythema
- In multivariate analysis only female gender (p=0.003) and alopecia (p=0.02) were independent predictors of worse global HRQoL




























What are the individual responses telling us?







_

PROCLIPI: HRQoL Update









PROPOSAL

DEVELOP A SKIN LYMPHOMA SPECIFIC QOL QUESTIONNAIRE JOINT EORTC CLTF & EORTC QOL GROUP

<u>Leads</u>: Simone Oerlemans, Julia Scarisbrick, **Co-Investigators:** Constanze Jonak, Antonio Cozzio, Ulrike Wehkemp & Pietro Quaglino

Grant awarded by EORTC 2019





EORTC/CTLF QOL Questionnaire specific for Cutaneous Lymphoma

For all skin lymphoma, cover low grade B-cell, early stage MF, advanced MF/SS and aggressive B-cell

- CTCL other than MF and CBCL may only have more minor HRQoL issues and must be Qs to reflect all stages
- Questionnaire has to (be):
- ✓ Not time consuming
- ✓ Easy to understand and to complete
- ✓ Specific for the disease
- ✓ Consider age and gender differences
- ✓ Validated
- ✓ Translation into national languages




<mark>Network</mark> Hematological Diseases (ERN EuroBloodNet)





How can we currently improve HRQoL?

O Network




Supportive Care to improve HRQoL

A holistic approach to treatment aiming to improve HRQoL should include symptom, emotional and functional support

- Pruritus treatment for itching
 - Moisturisers
 - Antihistamines, doxepin
 - Gabapentin
 - Apreptitant, Mirtrazapine
 - Naltrexone
- Skin infections treatment
 - Anti-bacterial agents
 - Anti-viral agents
 - Bleach baths
- Pain relief
 - Paracetamol / Codeine
 - Morphine
 - Insomnia help with sleeping ٠
 - Counselling
 - Sleeping tablets
 - Functional support
 - Dressings
 - Pain Relief
 - Physiotherapy
- Psychological support
 - Cancer psychologist
 - Patient help groups
 - Antidepressants






Skin infections - Staph aureus



Depression



Living with a

cancer

diagnosis



Pruritus





Painful hands






for rare or low prevalence complex diseases Network



JENNI TALK







Discussion









Questions

Correct answer question Health Related Quality of life (HRQOL)in CTCL is entirely related to symptom burden True / False Answer – false also includes emotions and functions

Opinion questions

Which of the following do you believe to be more important factor in improving HRQOL in CTCL patients in the future ?

- a) Improving survival
- b) Better treatment responses
- c) Improved symptom relief

How should we currently best improve HRQOL?

- a) Offer psychological support
- b) Improve patient information
- c) Offer more symptomatic treatment alongside anti CTCL therapy



Network Hematological Diseases (ERN EuroBloodNet) Webinars **Cutaneous Lymphoma** EuroBleedNet[®] Topic on Focus



















